228 related articles for article (PubMed ID: 37408496)
1. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Trsova I; Hrustincova A; Krejcik Z; Kundrat D; Holoubek A; Staflova K; Janstova L; Vanikova S; Szikszai K; Klema J; Rysavy P; Belickova M; Kaisrlikova M; Vesela J; Cermak J; Jonasova A; Dostal J; Fric J; Musil J; Dostalova Merkerova M
Mol Oncol; 2023 Dec; 17(12):2565-2583. PubMed ID: 37408496
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
4. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
[TBL] [Abstract][Full Text] [Related]
5. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
6. Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms.
Wedge E; Ahmadov U; Hansen TB; Gao Z; Tulstrup M; Côme C; Nonavinkere Srivatsan S; Ahmed T; Jespersen JS; Schlotmann BC; Schöllkopf C; Raaschou-Jensen K; Ødum N; Kjems J; Bak RO; Walter MJ; Grønbæk K; Kristensen LS
Leukemia; 2023 May; 37(5):1113-1125. PubMed ID: 36922625
[TBL] [Abstract][Full Text] [Related]
7.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
8. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
11. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
12. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
13. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
14. A variant erythroferrone disrupts iron homeostasis in
Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
[TBL] [Abstract][Full Text] [Related]
15. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
16. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
[TBL] [Abstract][Full Text] [Related]
17. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
18. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
20. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
Duetz C; Westers TM; In 't Hout FEM; Cremers EMP; Alhan C; Venniker-Punt B; Visser-Wisselaar HA; Chitu DA; de Graaf AO; Smit L; Jansen JH; van de Loosdrecht AA
Br J Haematol; 2021 May; 193(4):798-803. PubMed ID: 33765355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
